Figure 3From: A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumorsMean MK-2206 plasma concentration profiles following administration of MK-2206 in combination with trastuzumab. Linear scale of plasma concentration following administration of MK-2206, in every other day (QOD) and every week (QW) schedules, in combination with trastuzumab.Back to article page